​

Altimmune (ALT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALT Stock Forecast

Altimmune (ALT) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $23.60, with a high of $35.00 and a low of $12.00. This represents a 418.68% increase from the last price of $4.55.

- $7 $14 $21 $28 $35 High: $35 Avg: $23.6 Low: $12 Last Closed Price: $4.55

ALT Stock Rating

Altimmune stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (76.92%), 3 Hold (23.08%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 3 10 0 Strong Sell Sell Hold Buy Strong Buy

ALT Price Target Upside V Benchmarks

TypeNameUpside
StockAltimmune418.68%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$4.55$4.55$4.55
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25352--10
Mar, 25352--10
Feb, 25351--9
Jan, 25351--9
Dec, 24342--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 02, 2024Patrick TrucchioH.C. Wainwright$12.00$10.2317.30%163.74%
Dec 01, 2022Goldman Sachs$20.00$9.95101.01%339.56%
Nov 11, 2022JMP Securities$26.00$11.12133.81%471.43%
Aug 31, 2022Jefferies$35.00$22.0858.51%669.23%
Aug 30, 2022Yasmeen RahimiPiper Sandler$25.00$18.9432.00%449.45%
Aug 17, 2022H.C. Wainwright$50.00$17.66183.13%998.90%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 22, 2024Piper SandlerBuyBuyhold
Aug 12, 2024B. RileyBuyBuyhold
Jun 25, 2024B. RileyBuyBuyhold
Jun 24, 2024JMP SecuritiesOutperformOutperformhold
Jun 21, 2024Piper SandlerMarket OutperformMarket Outperformhold
Apr 02, 2024H.C. WainwrightBuyBuyhold
Dec 20, 2022Piper SandlerOverweightOverweighthold
Dec 01, 2022Goldman SachsBuyinitialise
Nov 11, 2022JMP SecuritiesMarket OutperformMarket Outperformhold
Aug 30, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.91$-2.33$-1.81$-1.66$-1.34----
Avg Forecast$-2.56$-2.41$-2.00$-1.50$-1.36$-1.49$-1.59$-1.28$3.13
High Forecast$-2.56$-2.41$-2.00$-1.32$-1.28$1.13$-1.11$-0.55$3.13
Low Forecast$-2.56$-2.41$-2.00$-1.65$-1.41$-2.54$-2.17$-1.98$3.13
Surprise %-25.39%-3.32%-9.50%10.67%-1.47%----

Revenue Forecast

$-50M $60M $170M $280M $390M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.19M$4.41M$-68.00K$426.00K$20.00K----
Avg Forecast$7.69M$1.18M$34.86K$341.86K$1.43K$3.33K$4.12K$55.22M$469.00M
High Forecast$7.69M$1.18M$34.86K$341.86K$1.43K$3.33K$4.12K$55.22M$469.00M
Low Forecast$7.69M$1.18M$34.86K$333.31K$1.43K$3.33K$4.12K$55.22M$469.00M
Surprise %6.43%274.08%-295.08%24.61%1299.58%----

Net Income Forecast

$-150M $-80M $-10M $60M $130M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-49.04M$-96.17M$-84.71M$-88.45M$-95.06M----
Avg Forecast$-58.66M$-128.50M$-94.20M$-88.45M$-71.62M$-102.93M$-87.32M$-67.21M$166.84M
High Forecast$-46.93M$-128.50M$-75.36M$-70.76M$-68.41M$60.19M$-59.10M$-29.04M$166.84M
Low Forecast$-70.39M$-128.50M$-113.04M$-106.14M$-74.82M$-135.22M$-115.55M$-105.38M$166.84M
Surprise %-16.39%-25.16%-10.07%-32.73%----

ALT Forecast FAQ

Is Altimmune stock a buy?

Altimmune stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Altimmune is a favorable investment for most analysts.

What is Altimmune's price target?

Altimmune's price target, set by 13 Wall Street analysts, averages $23.6 over the next 12 months. The price target range spans from $12 at the low end to $35 at the high end, suggesting a potential 418.68% change from the previous closing price of $4.55.

How does Altimmune stock forecast compare to its benchmarks?

Altimmune's stock forecast shows a 418.68% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Altimmune over the past three months?

  • April 2025: 30.00% Strong Buy, 50.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 30.00% Strong Buy, 50.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Altimmune’s EPS forecast?

Altimmune's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.49, marking a 11.19% increase from the reported $-1.34 in 2024. Estimates for the following years are $-1.59 in 2026, $-1.28 in 2027, and $3.13 in 2028.

What is Altimmune’s revenue forecast?

Altimmune's average annual revenue forecast for its fiscal year ending in December 2025 is $3.33K, reflecting a -83.33% decrease from the reported $20K in 2024. The forecast for 2026 is $4.12K, followed by $55.22M for 2027, and $469M for 2028.

What is Altimmune’s net income forecast?

Altimmune's net income forecast for the fiscal year ending in December 2025 stands at $-103M, representing an 8.28% increase from the reported $-95.059M in 2024. Projections indicate $-87.325M in 2026, $-67.212M in 2027, and $166.84M in 2028.